Latest Industry Insights

While in vitro tests and animal models can give some indication of potential drug safety issues, they do not always translate well to humans. Ignota Labs is tackling this challenge.

In this interview, Jeroen Verheyen tells us about Semarion, its SemaCyte technology and how it can help to address unmet drug screening needs.

In this interview, Technology Networks spoke to Karim Aly, CEO of Noze to find out more about replicating human odor perception and the benefits of breath-based disease detection.

Until recently, a lack of specialized services meant there was no definitive method for safely and effectively decontaminating plastic waste for reuse in new consumables. As a result, this waste was incinerated or diverted to landfill. The start-up company LabCycle has tackled this issue head-on, with its innovative approach to laboratory waste management. Technology Networks recently had the pleasure of speaking with LabCycle’s co-founder and chief technology officer Dr. Helen Liang, to learn more about its circular economy for laboratory plastic waste.

Neil Ward tells us about the role that genomics can play in conserving biodiversity and how innovative technologies such as HiFi sequencing are helping biodiversity projects.

We interview Raffaello Sbordoni, research scientist at Revivocell, to dive deeper into how high-complexity in vitromodels are supporting pharmaceutical development and their future potential.

At ELRIG’s Research & Innovation 2024 event, Technology Networks spoke to Dr. Véronique De Conto, project leader in in vitro pharmacology at HCS Pharma, to learn more about their powerful tools for in vitro metastasis propagation.

In this interview, Erik Digman Wiklund tells us about the discovery of circRNA and discusses some of the challenges of harnessing its full potential for therapeutic interventions.

At the European Laboratory Research and Innovation Group’s (ELRIG) Research and Innovation 2024 event, we asked a selection of start-up companies in the biotech space the same question: what are the key challenges you currently face?

We spoke with Dr. Bryan Oronsky, chief development officer at EpicentRx, to discover more about the promise of multipurpose drugs and the potential of EpicentRx’s nibrozetone (RRx-001) for several conditions.